Orasis Pharmaceuticals announced that Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a corrective prescription eye drop for the treatment of presbyopia in adults, is now available to prescribe in the United States. 

According to the company, its proprietary “EyeQ Formulation” is designed to maximize efficacy while minimizing side effects by balancing an approved concentration of pilocarpine at a near neutral pH for optimal bioavailability, is preservative-free in single-use vials, and includes lubricants (HA & HPMC) for comfort. Patients have the flexibility of using one drop of Qlosi in each eye for improved near vision for a specific occasion or activity, and up to 2 drops per day for an extended effect, lasting up to 8 hours.

Patients can fill prescriptions via two pharmacy partners, BlinkRx and Medvantx, and receive free home delivery, according to Orasis. Qlosi is available in single-use vials that can be taken on-the-go.